Mimedx (MDXG) Non-Current Deferred Tax Liability (2016)

Mimedx (MDXG) posted Non-Current Deferred Tax Liability of $1.1 million for Q4 2016.

Mimedx (MDXG) Non-Current Deferred Tax Liability (2016) Analysis & Trends

Mimedx has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $1.1 million in Q4 2016.

Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.1 million in Q4 2016, while the trailing twelve-month figure through Dec 2016 was $1.1 million (changed N/A YoY) and the FY2016 annual result came in at $1.1 million, changed N/A from the prior year.
Non-Current Deferred Tax Liability steadied at $1.1 million in Q4 2016 per MDXG's latest filing.
Over five years, Non-Current Deferred Tax Liability peaked at $1.1 million in Q4 2016 and troughed at $1.1 million in Q4 2016.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn

Download Data

Date	Value
Dec 31, 2016	1.13 Mn
Dec 31, 2016	1.13 Mn